title: [Efficacy and safety of propiverine on improvement of symptoms and QOL for female patients with wet overactive bladder].
abstract: The present study was prospectively conducted for female patients with wet overactive bladder to assess the efficacy of propiverine hydrochloride in improving their symptoms and quality of life (QOL). Propiverine hydrochloride was administered orally to 58 patients for 8 weeks. Prior to administration and at 4 and 8 weeks after administration, symptoms and QOL were assessed by the micturition diary, the International Consultation on Incontinence-Short Form (ICIQ-SF), and the King's Health Questionnaire (KHQ). After administration, numbers of daily micturitions, incontinence episodes, urgency episodes and severity of urgency which were assessed based on the micturition diary and urgency scale questionnaire showed significant improvement when compared to baseline values. Furthermore, both ICIQ-SF and KHQ scores improved significantly after administration. The incidence of adverse events was 23.8% and none were serious. Propiverine hydrochloride was shown to contribute not only to the improvement of symptoms in female patients with wet overactive bladder but also to their QOL.
authors.affiliation: Department of Urology, Shakaihoken Chukyo Hospital.
authors.forename: Masashi
authors.initials: M
authors.lastname: Kato
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Matsukawa
authors.forename: Kumiko
authors.initials: K
authors.lastname: Kato
authors.forename: Atsuo
authors.initials: A
authors.lastname: Kondo
authors.forename: Shin
authors.initials: S
authors.lastname: Yamada
authors.forename: Ryohei
authors.initials: R
authors.lastname: Hattori
authors.forename: Momokazu
authors.initials: M
authors.lastname: Gotoh
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001561:Benzilates / Q000008:administration & dosage / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010276:Parasympatholytics / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D011788:Quality of Life; D011795:Surveys and Questionnaires; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014550:Urinary Incontinence, Stress / Q000188:drug therapy
chemical_list: D001561:Benzilates; D018680:Cholinergic Antagonists; D010276:Parasympatholytics; C015586:propiverine